



## Epizyme to Participate in Upcoming Healthcare Conferences in March

March 2, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2022-- [Epizyme](#), (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced its participation in two investor conferences in March.

### **Cowen 42nd Annual Health Care Conference**

Shefali Agarwal, Chief Medical Officer, will participate in the Cowen 42<sup>nd</sup> Annual Health Care Conference as part of the Targeted Oncology panel. Tuesday, March 8, at 9:10am EST

### **Barclays Global Healthcare Conference**

Grant Bogle, Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference. Tuesday, March 15, 2022, at 2:05pm EST

Live webcasts of the presentations will be available under the investor section of the Company's website at [www.epizyme.com](http://www.epizyme.com), and will be archived for 60 days following the event.

### **About Epizyme, Inc.**

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit [www.epizyme.com](http://www.epizyme.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220228005306/en/): <https://www.businesswire.com/news/home/20220228005306/en/>

### **Media:**

Erin Graves  
[media@epizyme.com](mailto:media@epizyme.com)  
(617) 500-0615

### **Investors:**

Caitlin Stern  
[csstern@realchemistry.com](mailto:csstern@realchemistry.com)

Source: Epizyme, Inc.